EGFR and non-small cell lung carcinoma: To the best of our knowledge, this was the first study in the Latin-American population that compared the cost-effectiveness of first-line treatment TKI’s (gefitinib, erlotinib, and afatinib) for EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC patients.